Hydroxychloroquine in Psoriasis: Is it Really Harmful?

Sorbara, Stefania; Cozzani, Emanuele; Rebora, Alfredo; Parodi, Aurora

doi:10.2340/00015555-0141

Cited by 12 publications

(7 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A similar effect of antimalarial treatment on psoriasis and psoriatic arthritis has been observed by others [18][19][20][21][22] but exacerbations of psoriasis during antimalarial treatment have also been described [23][24][25][26][27]. These contradictory effects of antimalarials in the treatment of psoriasis were first reported in the literature about chloroquine in 1966 [28].…”

Section: Discussionsupporting

confidence: 66%

Successful Treatment of Psoriasis-like Lesions in HIV Infected Patients in Uganda with Chloroquine

Shihab¹,

Feld

Lutwama

et al. 2009

TOIDJ

View full text Add to dashboard Cite

Abstract:The effect of chloroquine in the treatment of psoriasis remains controversial. Treatment of psoriasis in HIV infection is not well described. Chloroquine has been shown to have direct effects on both the Human Immunodeficiency Virus (HIV) and on the psoriasis disease process. The effect of chloroquine in HIV infected patients with psoriasis has not been well studied.We report on the effect of chloroquine on psoriasis-like lesions in three HIV infected patients who were not on antiretroviral therapy. Three consecutive HIV positive patients with CD4 cell count below 200cells/mm 3 had unequivocal improvement of their psoriasis-like lesions after 2 weeks of a daily dose of 150mg of chloroquine.In conclusion, chloroquine may be useful in the treatment of psoriasis-like lesions in patients with HIV infection particularly in resource poor settings. Ideally, a controlled clinical trial will be needed to confirm this.

show abstract

Section: Discussionsupporting

confidence: 66%

Successful Treatment of Psoriasis-like Lesions in HIV Infected Patients in Uganda with Chloroquine

Shihab¹,

Feld

Lutwama

et al. 2009

TOIDJ

View full text Add to dashboard Cite

show abstract

“…However, these reactions are not always found to occur (Baker, 1966), and because arthritis and lupus are comorbidities of psoriasis, psoriasis patients occasionally receive treatment with this drug. One interesting case study indicates that chloroquine led to a reduction in symptoms of both lupus and psoriasis (Sorbara et al, 2006). It is important to stress, therefore that although we believe the drugs identified by our approach may be effective for psoriasis, this does not eliminate the need for in vivo and in vitro studies.…”

Section: Discussionmentioning

confidence: 88%

Drug Repurposing Prediction for Immune-Mediated Cutaneous Diseases using a Word-Embedding–Based Machine Learning Approach

Patrick

Raja

Miller

et al. 2019

Journal of Investigative Dermatology

View full text Add to dashboard Cite

Immune-mediated diseases affect more than 20% of the population, and many autoimmune diseases affect the skin. Drug repurposing (or repositioning) is a cost-effective approach for finding drugs that can be used to treat diseases for which they are currently not prescribed. We implemented an efficient bioinformatics approach using word embedding to summarize drug information from more than 20 million articles and applied machine learning to model the drug-disease relationship. We trained our drug repurposing approach separately on nine cutaneous diseases (including psoriasis, atopic dermatitis, and alopecia areata) and eight other immunemediated diseases and obtained a mean area under the receiver operating characteristic of 0.93 in crossvalidation. Focusing in particular on psoriasis, a chronic inflammatory condition of skin that affects more than 100 million people worldwide, we were able to confirm drugs that are known to be effective for psoriasis and to identify potential candidates used to treat other diseases. Furthermore, the targets of drug candidates predicted by our approach were significantly enriched among genes differentially expressed in psoriatic lesional skin from a large-scale RNA sequencing cohort. Although our algorithm cannot be used to determine clinical efficacy, our work provides an approach for suggesting drugs for repurposing to immune-mediated cutaneous diseases.

show abstract

“…Hydroxychloroquine also has efficacy in cutaneous lupus, with 50% of patients experiencing improvement (grade B evidence), but its utility in psoriasis is questionable [16]. There is one report of the successful treatment of psoriasis and SCLE with hydroxychloroquine (grade D evidence) [28]. Yet, there are other reports of hydroxychloroquine causing worsening of psoriasis or pustular flares (grade D evidence) [29, 30].…”

Section: Resultsmentioning

confidence: 99%

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1

Strober

Cather

Cohen

et al. 2012

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

IntroductionTraditional clinical trials in psoriasis exclude a significant proportion of patients with complex disease and comorbidities. A consensus panel of 14 experts in the field of psoriasis was formed to conduct a Delphi method exercise to identify difficult-to-treat psoriasis clinical scenarios and to rank treatment approaches.MethodsThe exercise consisted of both survey questionnaires and a live meeting to review and discuss current data (as of 2009, when the exercise was conducted) and arrive at a consensus for optimal treatment options. Seventy difficult treatment scenarios were identified, and the top 24 were selected for discussion at the live meeting.ResultsSix of the 24 discussed case scenarios are presented in this article (another five are presented in Part 2): (1) psoriasis with human papilloma virus-induced cervical or anogenital dysplasia; (2) concomitant psoriasis and systemic lupus erythematosus; (3) severe psoriatic nail disease causing functional or emotional impairment; (4) psoriasis therapies that potentially reduce cardiovascular morbidity and mortality; (5) older patients (≥65 years of age) with psoriasis; and (6) severe scalp psoriasis that is unresponsive to topical therapy.ConclusionThe Delphi exercise resulted in guidelines for practicing physicians to utilize when confronted with challenging patients with psoriasis.

show abstract

Hydroxychloroquine in Psoriasis: Is it Really Harmful?

Cited by 12 publications

References 13 publications

Successful Treatment of Psoriasis-like Lesions in HIV Infected Patients in Uganda with Chloroquine

Successful Treatment of Psoriasis-like Lesions in HIV Infected Patients in Uganda with Chloroquine

Drug Repurposing Prediction for Immune-Mediated Cutaneous Diseases using a Word-Embedding–Based Machine Learning Approach

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1

Contact Info

Product

Resources

About